Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nogapendekin Alfa Inbakicept in Sepsis with Persistent Lymphopenia
NCT07578558Phase 2Not yet recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Jul 2026
- Primary completion
- Aug 2027
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept in sepsis, sponsored by ImmunityBio, Inc.. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT07578558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07578558.